An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management


The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

Publication DOI:
Divisions: College of Health & Life Sciences > Aston Pharmacy School
College of Health & Life Sciences
College of Health & Life Sciences > Chronic and Communicable Conditions
Additional Information: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency (FP7/2007-2013) under grant Project Reference 286852.
Uncontrolled Keywords: BPR,cholecalciferol,efficacy,regulation No. 528/2012,transdermal,rodenticide,Pharmaceutical Science
Publication ISSN: 1873-3476
Last Modified: 15 Apr 2024 07:13
Date Deposited: 05 May 2015 12:05
Full Text Link:
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2015-06-20
Published Online Date: 2015-03-30
Authors: Davies, J.
Ingham, A.

Export / Share Citation


Additional statistics for this record